Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature


      • We perform a systematic review of incretin-based therapies and cognitive function.
      • GLP-1 showed positive effects on cerebral glucose metabolism.
      • DPP-IV inhibitors were associated with improved cognition in observational research.
      • We argue for powered clinical trials in patients with- and without diabetes.


      We performed a PRISMA systematic review of incretin-based therapies and effects on neurocognitive function in humans. There was observational evidence to support dipeptidyl peptidase-IV inhibitors in improving cognition, whilst glucagon-like peptide-1 had positive effects on cerebral glucose metabolism. Powered clinical trials are now needed in patients with- and without diabetes.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Primary Care Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Prince M.
        • Bryce R.
        • Albanese E.
        • et al.
        The global prevalence of dementia: a systematic review and metaanalysis.
        Alzheimers Dement. 2013; 9 (e2): 63-75
        • Scarpini E.
        • Scheltens P.
        • Feldman H.
        Treatment of Alzheimer’s disease: current status and new perspectives.
        Lancet Neurol. 2003; 2: 539-547
        • Lovshin J.A.
        • Drucker D.J.
        Incretin-based therapies for type 2 diabetes mellitus.
        Nat. Rev. Endocrinol. 2009; 5: 262-269
        • Yang Y.
        • Zhang J.
        • Ma D.
        • et al.
        Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes.
        J. Alzheimers Dis. 2013; 37: 637-648
        • Kosaraju J.
        • Holsinger R.M.
        • Guo L.
        • Tam K.Y.
        Linagliptin a dipeptidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD Mouse Model of Alzheimer’s disease.
        Mol. Neurobiol. 2016; (Epub ahead of print)https://doi.org/10.1007/s12035-016-0125-7
        • Aviles-Olmos I.
        • Dickson J.
        • Kefalopoulou Z.
        • et al.
        Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease.
        J. Parkinsons Dis. 2014; 4: 337-344
        • Gejl M.
        • Gjedde A.
        • Egefjord L.
        • et al.
        In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial.
        Front. Aging Neurosci. 2016; 24 p: p108
        • Rizzo M.R.
        • Barbieri M.
        • Boccardi V.
        • et al.
        Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment.
        J. Gerontol. A Biol. Sci. Med. Sci. 2014; 69: 1122-1131
        • Tasci I.
        • Naharci M.I.
        • Bozoglu E.
        • et al.
        Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes.
        Endocr. Metab. Immune Disord. Drug Targets. 2013; 13: 256-263
        • Mansur R.B.
        • Ahmed J.
        • Cha D.S.
        • et al.
        Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study.
        J. Affect. Disord. 2017; 207: 114-120
        • Farr O.M.
        • Sofopoulos M.
        • Tsoukas M.A.
        • et al.
        GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
        Diabetologia. 2016; 59: 954-965
        • Daniele G.
        • Iozzo P.
        • Molina-Carrion M.
        • et al.
        Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system.
        Diabetes. 2015; 64: 3406-3412
      1. U.S. National Institutes of Health. https://clinicaltrials.gov/. (Accessed 2 December 2016).

        • Moulton C.D.
        Prevention and management of cognitive impairment in people with type 2 diabetes: an evidence-based guide for primary care.
        Diabetes Prim. Care. 2016; 18: 75-79
        • Moulton C.D.
        • Pickup J.C.
        • Amiel S.A.
        • et al.
        Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: findings from the South London Diabetes (SOUL-D) Study.
        Prim. Care Diabetes. 2016; 10: 156-159